AQST Aquestive Therapeutics, Inc. Stock Quote

AQST [NASD]

Index	-	P/E	-	EPS (ttm)	-1.53	Insider Own	4.40%	Shs Outstand	33.62M	Perf Week	-5.50%
Market Cap	184.21M	Forward P/E	-	EPS next Y	-1.69	Insider Trans	-4.45%	Shs Float	29.64M	Perf Month	-5.86%
Income	-48.10M	PEG	-	EPS next Q	-0.26	Inst Own	57.30%	Short Float	4.21%	Perf Quarter	-29.36%
Sales	55.10M	P/S	3.34	EPS this Y	11.80%	Inst Trans	-3.20%	Short Ratio	1.37	Perf Half Y	-35.66%
Book/sh	-1.09	P/B	-	EPS next Y	-26.10%	ROA	-74.80%	Target Price	-	Perf Year	41.48%
Cash/sh	0.46	P/C	10.77	EPS next 5Y	-	ROE	226.50%	52W Range	1.41 - 9.47	Perf YTD	-6.92%
Dividend	-	P/FCF	-	EPS past 5Y	-36.50%	ROI	-106.20%	52W High	-47.39%	Beta	-
Dividend %	-	Quick Ratio	1.50	Sales past 5Y	90.00%	Gross Margin	69.20%	52W Low	253.19%	ATR	0.49
Employees	232	Current Ratio	1.70	Sales Q/Q	-33.10%	Oper. Margin	-67.30%	RSI (14)	41.69	Volatility	10.33% 8.67%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	33.10%	Profit Margin	-87.20%	Rel Volume	1.28	Prev Close	5.29
Shortable	Yes	LT Debt/Eq	-	Earnings	Mar 09 AMC	Payout	-	Avg Volume	911.76K	Price	4.98
Recom	1.80	SMA20	-13.16%	SMA50	-13.69%	SMA200	-16.81%	Volume	1,170,796	Change	-5.86%

Apr-22-19

Initiated

H.C. Wainwright

Buy

Jan-03-19

Initiated

Lake Street

Buy

$14

Aug-20-18

Initiated

RBC Capital Mkts

Outperform

$23

Aug-20-18

Initiated

JMP Securities

Mkt Outperform

$29

Mar-02-21 04:02PM	AQST INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Aquestive Therapeutics, Inc. GlobeNewswire -5.86%
12:30PM	Will Aquestive Therapeutics (AQST) Report Negative Earnings Next Week? What You Should Know Zacks
11:15AM	AQST Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Aquestive Therapeutics, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm ACCESSWIRE
Mar-01-21 11:27PM	Pomerantz Law Firm Announces the Filing of a Class Action against Aquestive Therapeutics, Inc. and Certain Officers - AQST PR Newswire +15.50%
Feb-25-21 11:07AM	Aquestive Sees Libervant Application Resubmission By End Of Q2 Benzinga -8.11%
07:30AM	Aquestive Therapeutics Reaffirms Near-Term NDA Resubmission for Libervant (diazepam) Buccal Film Following FDA Feedback GlobeNewswire
Feb-17-21 07:30AM	Aquestive Therapeutics to Announce Fourth Quarter and Year End 2020 Financial Results and Recent Business Highlights on March 9 and Host Conference Call on March 10 at 8:00 a.m. ET GlobeNewswire
Feb-09-21 07:30AM	Aquestive Therapeutics Strengthens Board of Directors with Appointments of Julie Krop, M.D., and Marco Taglietti, M.D., and Announces Resignation of Douglas K. Bratton from Board of Directors GlobeNewswire
Jan-28-21 10:12AM	New Strong Sell Stocks for January 28th Zacks -6.72%
07:30AM	Aquestive Therapeutics Appoints Mark Lepore, MD, as Chief Medical Officer for Allergy GlobeNewswire
Jan-21-21 08:30AM	Mitsubishi Tanabe Pharma America and Aquestive Therapeutics Announce U.S. Licensing and Supply Deal for Riluzole Oral Film for ALS Treatment PR Newswire
Jan-07-21 07:30AM	Aquestive Therapeutics Provides Business Update GlobeNewswire
Jan-06-21 12:22AM	Would Shareholders Who Purchased Aquestive Therapeutics' (NASDAQ:AQST) Stock Year Be Happy With The Share price Today? Simply Wall St. -6.58%
Jan-04-21 07:30AM	Aquestive Therapeutics to Present at Two Upcoming Investor Conferences GlobeNewswire
Dec-16-20 08:00AM	Aquestive Therapeutics Announces Departure of Chief Financial Officer and Appointment of Interim Chief Financial Officer GlobeNewswire -5.41%
Dec-07-20 10:21PM	Should I Buy Aquestive Therapeutics, Inc. (AQST)? Insider Monkey
Nov-25-20 09:15AM	Aquestive Therapeutics to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference GlobeNewswire
Nov-23-20 07:00AM	Aquestive Therapeutics Receives First Milestone Payment from KYNMOBI Monetization GlobeNewswire
Nov-19-20 08:17AM	The Daily Biotech Pulse: Aquestive's Positive FDA Meeting, Prevail Awarded Patent, Neuro-Oncology Conference Gets Underway Benzinga +14.99%
Nov-18-20 04:01PM	Aquestive Therapeutics Completes FDA Type A Meeting on Libervant GlobeNewswire
Nov-07-20 07:39AM	Earnings Update: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Just Reported And Analysts Are Trimming Their Forecasts Simply Wall St.
Nov-05-20 10:02PM	Aquestive Therapeutics, Inc. (AQST) Q3 2020 Earnings Call Transcript Motley Fool
06:15AM	Aquestive Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Nov-04-20 07:55PM	Aquestive Therapeutics (AQST) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:30PM	Aquestive Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update GlobeNewswire
08:21AM	The Daily Biotech Pulse: Alzheimer's Conference Underway, Biogen's Aducanumab Briefing Doc, Supernus Earnings Benzinga
Nov-03-20 07:00AM	Aquestive Therapeutics Signs Royalty Monetization Agreement with Marathon Asset Management for up to $125 Million GlobeNewswire +10.42%
Oct-28-20 12:33PM	Aquestive Therapeutics (AQST) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Oct-19-20 07:21AM	Aquestive Therapeutics, Inc. (NASDAQ:AQST): Is Breakeven Near? Simply Wall St. +6.96%
Oct-14-20 07:30AM	Aquestive Therapeutics to Announce Third Quarter Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ET GlobeNewswire
Sep-30-20 11:00AM	Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Aquestive Therapeutics, Inc. (AQST) Investigation ACCESSWIRE +10.09%
Sep-29-20 06:06PM	Aquestive Therapeutics: Libervant Will Eventually Be Approved, Says Analyst TipRanks -11.27%
Sep-28-20 04:25AM	Aquestive Plunges 37% As FDA Rejects Seizure Drug; Street Stays Bullish SmarterAnalyst -34.69%
Sep-25-20 05:38PM	Aquestive Therapeutics Receives Complete Response Letter from FDA for Libervant (diazepam) Buccal Film for Management of Seizure Clusters GlobeNewswire
08:51AM	Implied Volatility Surging for Aquestive Therapeutics (AQST) Stock Options Zacks
Sep-17-20 10:11AM	3 Strong Buy Healthcare Stocks With Major Catalysts Approaching TipRanks +13.94%
Aug-20-20 08:11AM	Are Insiders Buying Aquestive Therapeutics, Inc. (NASDAQ:AQST) Stock? Simply Wall St.
07:30AM	Aquestive Therapeutics Initiates Phase 1 Pharmacokinetic Trial of AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) In Development for Treatment of Allergic Reactions Including Anaphylaxis GlobeNewswire
Aug-18-20 11:06AM	Aquestive Therapeutics (AQST) in Focus: Stock Moves 6.4% Higher Zacks +6.79%
Aug-10-20 07:30AM	Aquestive Therapeutics Receives FDA Fast Track Designation for AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Treatment of Allergic Reactions Including Anaphylaxis GlobeNewswire +10.49%
Aug-05-20 06:31PM	Aquestive Therapeutics, Inc. (AQST) Q2 2020 Earnings Call Transcript Motley Fool +7.83%
Aug-04-20 07:35PM	Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:01PM	Aquestive Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update: AQST-108 Progress Remains On Track; Libervant PDUFA Goal Date Approaches GlobeNewswire
08:18AM	The Daily Biotech Pulse: Voyager, AbbVie End Collaboration, Thumbs Down For DBV's Peanut Allergy Patch, Tiziana Expedites COVID-19 Trial Plans Benzinga
Jul-28-20 04:15PM	Aquestive Therapeutics to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference GlobeNewswire
12:33PM	Aquestive Therapeutics (AQST) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Jul-15-20 07:57AM	Aquestive Therapeutics to Announce Second Quarter Financial Results and Recent Business Highlights on Aug 4 and Host Conference Call on Aug 5 at 8:00 a.m. ET GlobeNewswire +6.18%
Jul-06-20 09:49AM	What Is The Ownership Structure Like For Aquestive Therapeutics, Inc. (NASDAQ:AQST)? Simply Wall St.
Jun-29-20 07:00AM	Aquestive Therapeutics Files IND for Pharmacokinetic Clinical Trials of AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Anaphylaxis Treatment GlobeNewswire
Jun-25-20 11:22AM	Hedge Funds Arent Crazy About Aquestive Therapeutics, Inc. (AQST) Anymore Insider Monkey
Jun-16-20 08:00AM	Aquestive Therapeutics to Present at BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference GlobeNewswire
Jun-04-20 05:05PM	Aquestive Therapeutics to Hold Virtual-Only Annual Meeting of Stockholders GlobeNewswire
May-28-20 09:42AM	Implied Volatility Surging for Aquestive Therapeutics (AQST) Stock Options Zacks
May-27-20 09:22AM	Why Aquestive Therapeutics (AQST) Stock Might be a Great Pick Zacks
May-22-20 07:10AM	The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray Benzinga -6.50%
May-21-20 05:27PM	Aquestive Therapeutics Advances Royalty Monetization Plan as Sunovion Pharmaceuticals Apomorphine Sublingual Film Therapy Receives FDA Approval GlobeNewswire
May-20-20 11:30AM	Is Aquestive Therapeutics (AQST) Outperforming Other Medical Stocks This Year? Zacks
May-14-20 08:25AM	Aquestive Therapeutics' Shares March Higher, Can It Continue? Zacks
May-12-20 12:00PM	All You Need to Know About Aquestive Therapeutics (AQST) Rating Upgrade to Buy Zacks
May-08-20 08:15AM	Benzinga Pro's Top 5 Stocks To Watch For Fri., May 8, 2020: KC, IDXX, LAZY, AQST, AN Benzinga +10.04%
May-07-20 02:00PM	Aquestive Therapeutics to Present at 2020 RBC Capital Markets Global Healthcare Conference GlobeNewswire +8.33%
May-06-20 06:00PM	Aquestive Therapeutics, Inc. (AQST) Q1 2020 Earnings Call Transcript Motley Fool
May-05-20 04:05PM	Aquestive Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update: AQST-108 and Libervant Remain On Track GlobeNewswire
Apr-28-20 12:34PM	Will Aquestive Therapeutics (AQST) Report Negative Earnings Next Week? What You Should Know Zacks
Apr-26-20 07:51AM	3 Biotech Stocks Under $4 With Big Upside Potential TipRanks
Apr-21-20 09:15AM	Aquestive Therapeutics to Announce First Quarter Financial Results and Recent Business Highlights on May 5 and Host Investment Community Conference Call on May 6 GlobeNewswire
Apr-15-20 08:50AM	Aquestive Therapeutics (AQST): Strong Industry, Solid Earnings Estimate Revisions Zacks
Apr-14-20 09:13AM	Top Ranked Momentum Stocks to Buy for April 14th Zacks +11.28%
Mar-17-20 07:00AM	Memgen Appoints Gregory Brown as Chief Executive Officer Newsfile +15.58%
Mar-14-20 08:15AM	Aquestive Therapeutics, Inc. Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock? Simply Wall St.
Mar-13-20 10:23AM	Company News for Mar 13, 2020 Zacks -12.50%
Mar-11-20 06:25PM	Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates Zacks -14.53%
04:30PM	Aquestive Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights GlobeNewswire
Mar-05-20 12:30PM	Will Aquestive Therapeutics (AQST) Report Negative Earnings Next Week? What You Should Know Zacks
Mar-03-20 03:00PM	7 Cheap Stocks Under $7 With Massive Upside Potential Kiplinger
Feb-20-20 07:00AM	Aquestive Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights on March 12, 2020 GlobeNewswire
Feb-10-20 07:00AM	Aquestive Therapeutics Announces U.S. Food and Drug Administration Filing Acceptance of New Drug Application (NDA) for Libervant (diazepam) Buccal Film GlobeNewswire +17.93%
Feb-06-20 07:00AM	Aquestive Therapeutics Announces FDA Confirmed 505(b)(2) Pathway for AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Anaphylaxis Treatment GlobeNewswire
Jan-29-20 12:30PM	3 Healthcare Stocks That Can Double This Year TipRanks
Jan-12-20 06:16PM	Aquestive Therapeutics Receives FDA Response to Citizens Petition GlobeNewswire
Jan-10-20 06:30AM	Aquestive Therapeutics Exceeds Top End of Guidance Range for Preliminary Unaudited Full Year 2019 Total Revenues and Provides Initial Full Year 2020 Guidance GlobeNewswire
Dec-22-19 06:09PM	Did Hedge Funds Drop The Ball On Aquestive Therapeutics, Inc. (AQST) ? Insider Monkey
Dec-17-19 05:31AM	Did Changing Sentiment Drive Aquestive Therapeutics's (NASDAQ:AQST) Share Price Down By 22%? Simply Wall St.
Dec-12-19 08:00PM	Aquestive Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire -12.99%
Dec-11-19 07:21AM	The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint Benzinga
Dec-10-19 04:01PM	Aquestive Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
Dec-09-19 10:04AM	Top Ranked Momentum Stocks to Buy for December 9th Zacks
Dec-04-19 08:30AM	Aquestive Therapeutics to Host Investor & Analyst Libervant (diazepam) Buccal Film Update Forum at American Epilepsy Society 2019 Annual Meeting GlobeNewswire
Dec-03-19 07:59AM	The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial Benzinga
Dec-02-19 07:30AM	Aquestive Therapeutics Completes Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Libervant (diazepam) Buccal Film for Management of Seizure Clusters GlobeNewswire +12.20%
Nov-29-19 10:29AM	These 3 Biotech Stocks Could More Than Double in 2020, Says Wedbush TipRanks +7.15%
Nov-26-19 04:05PM	A Deep Dive Into Aquestive Following The FDA's Approval Of Riluzole Benzinga
11:27AM	Aquestive Therapeutics Announces Poster Presentations of Data on Libervant (diazepam) Buccal Film at American Epilepsy Society 2019 Annual Meeting GlobeNewswire
11:07AM	Company News For Nov 26, 2019 Zacks
Nov-25-19 08:56AM	Aquestive shares jump on FDA approval MarketWatch +17.26%
08:00AM	Aquestive Therapeutics Receives FDA Approval for Exservan (riluzole) Oral Film GlobeNewswire
Nov-24-19 04:19PM	The Week Ahead In Biotech: Aquestive Awaits FDA Decision, Arrowhead Earnings And More Benzinga
Nov-22-19 04:42PM	REFILE-FDA approves Aquestive's ALS treatment Reuters
Nov-14-19 01:31PM	Healthcare Drives Wall Street: 5 Soaring ETFs & Stocks Zacks
Nov-13-19 08:30AM	Aquestive Therapeutics Licenses Riluzole Oral Film to Zambon for Development and Commercialization in the EU for Patients with ALS GlobeNewswire

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of epileptic seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The company's proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation of epinephrine for the treatment of anaphylaxis; and AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly. It also develops APL-130277, a sublingual film formulation of apomorphine to treat Parkinson's disease. Aquestive Therapeutics, Inc. was founded in 2004 and is headquartered in Warren, New Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schobel Alexander Mark	Chief Innovation/Tech Officer	Feb 10	Sale	6.75	23,460	158,355	837,000	Feb 10 08:17 PM
Schobel Alexander Mark	Chief Innovation/Tech Officer	Feb 09	Sale	6.75	11,540	77,895	860,460	Feb 10 08:17 PM
Schobel Alexander Mark	Chief Innovation/Tech Officer	Feb 08	Sale	6.50	40,792	265,148	872,000	Feb 09 04:00 PM
Maxwell John T.	SVP-Chief Financial Officer	Aug 18	Sale	8.00	3,000	24,000	150,614	Aug 19 08:55 AM
Kendall Keith J	CEO and President	Jun 30	Option Exercise	0.00	333	0	639,297	Jul 02 04:00 PM
Schobel Alexander Mark	Chief Innovation/Tech Officer	Jun 30	Option Exercise	0.00	333	0	912,886	Jul 02 04:00 PM
Kendall Keith J	CEO and President	Jun 04	Sale	5.11	50,000	255,310	638,964	Jun 05 04:05 PM
Schobel Alexander Mark	Chief Innovation/Tech Officer	May 31	Option Exercise	0.00	14,572	0	916,685	Jun 02 05:14 PM
Kendall Keith J	CEO and President	May 31	Option Exercise	0.00	14,572	0	695,456	Jun 02 05:13 PM
Schobel Alexander Mark	Chief Innovation/Tech Officer	May 08	Sale	5.00	40,000	200,000	902,113	May 11 04:15 PM
Schobel Alexander Mark	Chief Innovation/Tech Officer	Apr 29	Sale	4.50	40,000	180,000	1,022,113	May 01 04:05 PM
Schobel Alexander Mark	Chief Innovation/Tech Officer	Apr 27	Sale	4.00	40,000	160,000	942,113	May 04 04:05 PM
Schobel Alexander Mark	Chief Innovation/Tech Officer	Apr 14	Sale	3.70	40,000	148,000	982,113	May 04 04:05 PM
Schobel Alexander Mark	Chief Innovation/Tech Officer	Mar 31	Option Exercise	0.00	329	0	1,062,210	Apr 02 04:16 PM
Kendall Keith J	CEO and President	Mar 31	Option Exercise	0.00	329	0	680,983	Apr 02 04:16 PM
BRAENDER LORI J	SVP, General Counsel	Mar 16	Buy	1.54	14,000	21,624	25,000	Mar 18 04:45 PM
Boyd Peter E.	SVP-Bus. Process & Info. Tech.	Mar 16	Buy	1.50	2,000	3,000	52,239	Mar 18 04:45 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience